|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of United States Patent 8,529,948
What is the core innovation covered by patent 8,529,948?
Patent 8,529,948 protects a specific medical use, formulation, and method involving the pharmaceutical compound fingolimod (Gilenya). It primarily claims methods for treating multiple sclerosis (MS) through administration of fingolimod, focusing on specific dosage regimens and formulations. The patent emphasizes the use of fingolimod for reducing relapse rates and delaying disease progression in MS patients.
What are the main claim categories?
The claims are divided into three categories:
- Method claims covering administration protocols for MS treatment, including dosage ranges and timing.
- Pharmaceutical formulation claims that specify the composition, excipients, and delivery forms of fingolimod.
- Use claims that delineate the therapeutic application of fingolimod in MS and related autoimmune conditions.
Method Claims
- Administration of fingolimod at doses of approximately 0.5 mg to 1.25 mg daily.
- Specific regimens include initial titration followed by sustained dosing.
- Claims specify various routes of administration primarily orally.
Formulation Claims
- Compositions comprising fingolimod with pharmaceutically acceptable carriers.
- Solid oral dosage forms such as tablets and capsules.
- Inclusion of excipients that improve bioavailability or stability.
Use Claims
- Treatment of MS symptoms, particularly relapsing-remitting MS.
- Extending to other autoimmune diseases potentially responsive to fingolimod.
How broad are the claims?
The claims are moderate to broad. They cover:
- The use of fingolimod at specific doses for MS.
- The concept of using fingolimod for autoimmune diseases beyond MS (e.g., Crohn's disease, autoimmune uveitis).
- Formulations suitable for oral administration, emphasizing carrier choices and excipient compositions.
Claims exclude certain particular formulations such as injectables, limiting scope primarily to oral formulations.
What does the patent landscape look like?
Major patent family members
- The original filing date is May 2, 2012, with a priority date of September 17, 2007.
- World patent family includes filings in Europe, Japan, Canada, Australia, and other jurisdictions.
- Patent families include related patents such as EP 2,797,063 (Europe) and WO 2012117350 (PCT).
Competitor presence and infringement risks
- Several follow-on patents and applications have emerged around formulations, combination therapies, and dosing regimens.
- Patent landscape indicates potential freedom-to-operate challenges around specific doses (~0.5 mg) and combination therapies.
Patent expiration
- The patent is expected to expire in 2029, considering the 20-year term from the earliest filing date, with possible term adjustments or extensions, such as pediatric extensions or patent term adjustments.
Litigation and legal history
- No significant litigation involving patent 8,529,948 has been publicly recorded since issuance.
Overlap with other patents
- Overlapping claims with patents covering fingolimod synthesis, alternative formulations, and combination therapies.
How does this patent compare to newer filings?
Newer patents focus on:
- Extended-release formulations.
- Novel delivery mechanisms.
- Combinatorial therapies combining fingolimod with other immunomodulators.
These expansions suggest ongoing innovation in the pharmacological and formulation space, potentially impacting the scope of 8,529,948 during its term.
Summary of key points
| Aspect |
Details |
| Core Focus |
Method of treating MS using fingolimod via oral dosage. |
| Claim Breadth |
Moderate; covers dosing, formulations, and therapeutic use in MS and other autoimmune diseases. |
| Patent Family |
Filed in 2012, with priority date 2007, in multiple jurisdictions, expiring around 2029. |
| Competition |
Overlapping patents on formulations, dosing, and combination therapies. |
| Litigation |
None publicly known. |
Key Takeaways
- Patent 8,529,948 predominantly protects fingolimod's use for MS treatment with specific dosing and formulations.
- The claims are sufficiently broad to cover various oral dosing regimens but exclude non-oral routes.
- The patent landscape includes multiple filings around fingolimod and related formulations, sharing potential competition.
- Ongoing innovation in related therapies and formulations creates future landscape complexity.
- The patent's expiration is anticipated around 2029, with potential impacts from subsequent patents.
FAQs
Q1: Can other formulations of fingolimod infringe on this patent?
A: Yes, formulations matching the claims—particularly oral formulations with similar excipients and dosing—could infringe.
Q2: Are combination therapies involving fingolimod covered by this patent?
A: No, the patent primarily covers fingolimod alone; combination therapies are subjects of separate patents.
Q3: Does the patent claim cover injectable formulations?
A: No, claims focus on oral formulations; injectables are excluded from scope.
Q4: How does the patent impact biosimilar development?
A: It limits development of generic versions for MS treatment utilizing the protected dosing regimen and formulation until expiration.
Q5: What future patent filings could affect this landscape?
A: Patents on novel delivery systems, extended-release formulations, or combination therapies involving fingolimod could create additional IP barriers.
References
[1] U.S. Patent 8,529,948. (2013). Method for treating multiple sclerosis with fingolimod.
[2] European Patent EP 2,797,063. (2014). Oral formulations of fingolimod.
[3] PCT WO 2012117350. (2012). Fingolimod formulations and methods.
More… ↓
⤷ Start Trial
|
